GRI Bio (GRI) Stock: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.90
-0.04 (-2.06%)
▼
5d:
-17.03%
30d:
-2.56%
90d:
-17.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GRI is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GRI is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.90, which is considered slightly high relative to its 30-day fair value range of $1.53 to $2.13.
Technical Outlook: Technically, GRI is in a downtrend. Immediate support is located at $1.76, while resistance sits at $3.36.
Market Sentiment: GRI scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.50 (+873.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is in a downtrend. Immediate support is located at $1.76, while resistance sits at $3.36.
Market Sentiment: GRI scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.50 (+873.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.53 -
$2.13
Company Quality Score
44/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (37/100)
- BULLISH: Trading 873.7% below Wall St target ($18.50)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.53 -
$2.13
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.76
Resistance Level
$3.36
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.94
Wall Street Target
$18.50
(+873.7%)
Share & Embed Analysis
Last updated: September 13, 2026 6:59 PM ET
Data refreshes hourly during market hours. Next update: 7:59 PM
Data refreshes hourly during market hours. Next update: 7:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
